Jubilant Organosys sells $200 million CB while pondering possible acquisition

Issue marks seventh CB from an Indian pharmaceutical company since December; conversion premiums still high.
Jubilant Organosys yesterday April 25 became the latest in growing line-up of Indian pharmaceutical companies to raise fresh capital from the sale of five-year convertible bonds as the industry prepares for another wave of expansion.

Jubilant, which also produces various chemicals and adhesives, raised $200 million from a bought deal arranged by JPMorgan which offered the bonds on to investors at fixed terms which included a 50% conversion premium. It was the fourth time since May 2004 that the company has raised cash from the sale of equity or equity-linked instruments, including two previous CBs that will mature in 2009 and 2010 respectively.

The stock hasnÆt had the same spectacular share price gains as...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222